Advances in targeted therapies for systemic sclerosis
XIAO Rong
LIU Jiani
Abstract：Systemic sclerosis(SSc),as an immune-mediated chronic connective tissue dis-ease,is mainly characterized by fibrosis of multiple organs,including the skin and lungs.It is a rare disease,with a high incidence and mortality among rheumatic immune diseases.At present,there is no effective drug for the treatment of SSC.In recent years,it has been found that the in-teractions between T/B lymphocytes,fibroblasts,endothelial cells,and various pro-inflammatory and fibrotic signaling molecules play a crucial role in the occurrence and development of SSc.On this basis,a series of targeted drugs are currently being tested.CD20 monoclonal antibodies(Rit-uximab),IL-6 receptor antagonists(Tocilizumab),and multi-target tyrosine kinase inhibitors(Nintedanib)have been approved for the treatment of SSc or SSc-ILD by FDA.In addition,other targeted drugs such as Janus kinase inhibitors and various interleukin inhibitors have shown pre-liminary therapeutic potentials through clinical trials.This article reviews the research progress in targeted therapies for SSc by synthesizing the latest evidence from four aspects:targeting B lym-phocytes,T lymphocytes,vascular endothelial cells,and pro-inflammatory and fibrotic signaling molecules.
Keywords：systemic sclerosistargeted therapybiologic agentssmall molecule com-pounds
Publication Date：2024-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：10( 287-296 )